{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04934683",
            "orgStudyIdInfo": {
                "id": "GUARDIAN INDUCTION AGENT"
            },
            "organization": {
                "fullName": "The Cleveland Clinic",
                "class": "OTHER"
            },
            "briefTitle": "GUARDIAN (NCT04884802) Sub-study, Etomidate vs Propofol",
            "officialTitle": "GUARDIAN (NCT04884802) Sub-study Comparing Etomidate and Propofol",
            "therapeuticArea": [
                "Other"
            ],
            "study": "guardian-sub-study-etomidate-vs-propofol"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-11",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-07-27",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-07",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-06-15",
            "studyFirstSubmitQcDate": "2021-06-15",
            "studyFirstPostDateStruct": {
                "date": "2021-06-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-11-01",
            "lastUpdatePostDateStruct": {
                "date": "2023-11-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "The Cleveland Clinic",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Some patients participating in the underlying GUARDIAN trial (NCT04884802) will be additionally randomized to etomidate vs propofol for anesthetic induction.",
            "detailedDescription": "Patients participating in the underlying GUARDIAN trial (NCT04884802) will be randomized to: 1) routine intraoperative blood pressure management (routine pressure management); or 2) norepinephrine or phenylephrine infusion to maintain intraoperative MAP \u226585 mmHg (tight pressure management). Patients participating in this sub-study will be additionally randomized to etomidate or propofol for induction of anesthesia."
        },
        "conditionsModule": {
            "conditions": [
                "Major Surgery"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "FACTORIAL",
                "primaryPurpose": "PREVENTION",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 6254,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Routine Pressure Management with etomidate induction",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Etomidate will be used as an induction agent.",
                    "interventionNames": [
                        "Procedure: Routine blood pressure control",
                        "Drug: Etomidate"
                    ]
                },
                {
                    "label": "Routine Pressure Management with propofol induction",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Propofol will be used as an induction agent.",
                    "interventionNames": [
                        "Procedure: Routine blood pressure control",
                        "Drug: Propofol"
                    ]
                },
                {
                    "label": "Tight Pressure Management with etomidate induction",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Etomidate will be used as an induction agent.",
                    "interventionNames": [
                        "Procedure: Tight blood pressure control",
                        "Drug: Etomidate"
                    ]
                },
                {
                    "label": "Tight Pressure Management with propofol induction",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Propofol will be used as an induction agent.",
                    "interventionNames": [
                        "Procedure: Tight blood pressure control",
                        "Drug: Propofol"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "PROCEDURE",
                    "name": "Routine blood pressure control",
                    "description": "Routine blood pressure control.",
                    "armGroupLabels": [
                        "Routine Pressure Management with etomidate induction",
                        "Routine Pressure Management with propofol induction"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Tight blood pressure control",
                    "description": "Tight blood pressure control.",
                    "armGroupLabels": [
                        "Tight Pressure Management with etomidate induction",
                        "Tight Pressure Management with propofol induction"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Etomidate",
                    "description": "Anesthetic induction with etomidate.",
                    "armGroupLabels": [
                        "Routine Pressure Management with etomidate induction",
                        "Tight Pressure Management with etomidate induction"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Propofol",
                    "description": "Anesthetic induction with propofol.",
                    "armGroupLabels": [
                        "Routine Pressure Management with propofol induction",
                        "Tight Pressure Management with propofol induction"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Composite of serious perfusion-related complications",
                    "description": "Composite of serious perfusion-related complications. Specifically, we will consider a collapsed (one or more) composite of myocardial injury after non-cardiac surgery (MINS), non-fatal cardiac arrest, stroke, Stage 2-3 acute kidney injury, sepsis, and all-cause mortality within 30 days of surgery.",
                    "timeFrame": "30 days after surgery"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Postoperative Delirium",
                    "description": "Delirium, defined by abnormal 3D CAM or CAM ICU (in ventilated patients) assessed twice daily during the initial four postoperative days.",
                    "timeFrame": "Initial four postoperative days"
                },
                {
                    "measure": "Major Adverse cardiac events",
                    "description": "Myocardial infarction, non-fatal cardiac arrest, stroke, and all-cause mortality.",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Cognition",
                    "description": "T-MOCA",
                    "timeFrame": "1 Year"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "ICU admission",
                    "description": "Admission.",
                    "timeFrame": "30 days."
                },
                {
                    "measure": "Hospital Readmission",
                    "description": "Readmission.",
                    "timeFrame": "30 days."
                },
                {
                    "measure": "Atrial Fibrillation",
                    "description": "Atrial Fibrillation.",
                    "timeFrame": "30 days."
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* At least 45 years old;\n* Scheduled for major noncardiac surgery expected to last at least 2 hours;\n* Having general anesthesia, neuraxial anesthesia, or the combination;\n* Expected to require at least overnight hospitalization (planned ICU admission is acceptable);\n* Are designated ASA physical status 2-4 (ranging from mild systemic disease through severe systemic disease that is a constant threat to life);\n* Chronically taking at least one anti-hypertensive medication;\n* Expected to have direct intraoperative blood pressure monitoring with an arterial catheter;\n* Cared for by clinicians willing to follow the GUARDIAN protocol;\n* Subject to at least one of the following risk factors:\n* Age \\>65 years;\n* History of peripheral arterial surgery;\n* History of coronary artery disease;\n* History of stroke or transient ischemic attack;\n* Serum creatinine \\>175 \u00b5mol/L (\\>2.0 mg/dl);\n* Diabetes requiring medication;\n* Current smoking or 15 pack-year history of smoking tobacco;\n* Scheduled for major vascular surgery;\n* Body mass index \u226535 kg/m2;\n* Preoperative high-sensitivity troponin T \\>14 ng/L or troponin I equivalent, defined as \u226515 ng/L (Abbott assay),77 19 ng/L (Siemens assay, \\[Borges, unpublished\\]), or 25% of the 99% percentile for other assays;\n* B-type natriuretic protein (BNP) \\>80 ng/L or N-terminal B-type natriuretic protein (NT-ProBNP) \\>200 ng/L.78,79\n\nExclusion Criteria:\n\n* Are scheduled for carotid artery surgery;\n* Are scheduled for intracranial surgery;\n* Are scheduled for partial or complete nephrectomy;\n* Are scheduled for pheochromocytoma surgery;\n* Are scheduled for liver transplantation;\n* Require preoperative intravenous vasoactive medications;\n* Have a condition that precludes routine or tight blood pressure management such as surgeon request for relative hypotension;\n* Require beach-chair positioning;\n* Have end-stage renal disease requiring dialysis or estimated glomerular filtration rate (eGFR) \\<30 ml/min;\n* Have a documented history of dementia;\n* Have language, vision, or hearing impairments that may compromise cognitive assessments;\n* Have contraindications to norepinephrine or phenylephrine per clinician judgement;\n* Have previously participated in this trial.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "45 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Fabio Rodriquez Patarroyo, MD",
                    "role": "CONTACT",
                    "phone": "216) 444-9674\u202c",
                    "email": "Rodrigf3@ccf.org"
                },
                {
                    "name": "Daniel I Sessler, MD",
                    "role": "CONTACT",
                    "phone": "216-870-2620",
                    "email": "sessled@ccf.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Daniel I Sessler, MD",
                    "affiliation": "The Cleveland Clinic",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Cleveland Clinic",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Fabio Rodriquez Patarroyo, MD",
                            "role": "CONTACT",
                            "phone": "216-444-9674",
                            "email": "Rodrigf3@ccf.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Data will be shared collaboratively.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF",
                "CSR",
                "ANALYTIC_CODE"
            ],
            "timeFrame": "2 years after publication.",
            "accessCriteria": "Contact PI."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000015742",
                    "term": "Propofol"
                },
                {
                    "id": "D000005045",
                    "term": "Etomidate"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006993",
                    "term": "Hypnotics and Sedatives"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018686",
                    "term": "Anesthetics, Intravenous"
                },
                {
                    "id": "D000018681",
                    "term": "Anesthetics, General"
                },
                {
                    "id": "D000000777",
                    "term": "Anesthetics"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4107",
                    "name": "Anesthetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M18307",
                    "name": "Propofol",
                    "asFound": "Inhibitor",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8190",
                    "name": "Etomidate",
                    "asFound": "Nicotine Replacement Therapy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10043",
                    "name": "Hypnotics and Sedatives",
                    "relevance": "LOW"
                },
                {
                    "id": "M20766",
                    "name": "Anesthetics, Intravenous",
                    "relevance": "LOW"
                },
                {
                    "id": "M20761",
                    "name": "Anesthetics, General",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}